Gene Expression and Chemotherapy Response in Multiple Myeloma
Author Information
Author(s): M.E. Linsenmeyer, S. Jefferson, M. Wolf, J.P. Matthews, P.G. Board, D.M. Woodcock
Primary Institution: Peter MacCallum Cancer Institute
Hypothesis
Is there a relationship between the expression levels of the mdrl gene and glutathione S-transferase genes and the response to chemotherapy in multiple myeloma patients?
Conclusion
Higher levels of the mdrl gene are associated with a failure to respond to chemotherapy in multiple myeloma patients.
Supporting Evidence
- Patients who failed to respond to initial chemotherapy had significantly higher levels of mdrl than patients who responded.
- mRNA levels for mdrl and GST-2 were significantly correlated.
- GST-3 and mdrl levels were weakly associated.
Takeaway
This study found that patients with higher levels of a specific gene related to drug resistance are less likely to respond to chemotherapy.
Methodology
The study analyzed mRNA levels in bone marrow samples from multiple myeloma patients and correlated these levels with chemotherapy response.
Limitations
The sample size was relatively small, and the study may not account for all factors influencing chemotherapy response.
Participant Demographics
Patients with multiple myeloma, some previously treated and some newly diagnosed.
Statistical Information
P-Value
0.01
Statistical Significance
p=0.01
Want to read the original?
Access the complete publication on the publisher's website